Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 24 of the 42 sources its claims cite were checked for support.
Abstract
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease. CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
Overview
CoChat Summary
TL;DR
In the PROMINENT trial, pemafibrate lowered triglyceride and remnant cholesterol levels but did not reduce cardiovascular events among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, low HDL cholesterol, and controlled LDL cholesterol. The trial was stopped early for futility, and pemafibrate was associated with more renal adverse events and venous thromboembolism.
Key findings
- Among 10,497 patients, a primary end-point event occurred in 572 patients in the pemafibrate group and 560 in the placebo group (hazard ratio, 1.03; 95% CI, 0.91 to 1.15; P=0.67), with no apparent effect modification in any prespecified subgroup.
- At 4 months, the relative between-group differences were −26.2% for triglycerides, −25.8% for VLDL cholesterol, −25.6% for remnant cholesterol, and −27.6% for apolipoprotein C-III; apolipoprotein B increased by 4.8%.
- Serious adverse events did not differ significantly overall (1970 vs. 1914; hazard ratio, 1.04; 95% CI, 0.98 to 1.11; P=0.23), but pemafibrate was associated with higher renal adverse events (1463 vs. 1347; hazard ratio, 1.12; 95% CI, 1.04 to 1.20; P=0.004) and venous thromboembolism (71 vs. 35; hazard ratio, 2.05; 95% CI, 1.35 to 3.17; P<0.001), and lower nonalcoholic fatty liver disease (155 vs. 200; hazard ratio, 0.78; 95% CI, 0.63 to 0.96; P=0.02).
Methods
- Multinational, double-blind, randomized, placebo-controlled, event-driven trial conducted at 876 clinical sites in 24 countries; 10,497 patients composed the intention-to-treat population after 41 randomized patients were excluded for Good Clinical Practice violations.
- Eligible patients had type 2 diabetes, fasting triglyceride levels of 200 to 499 mg per deciliter, HDL cholesterol ≤40 mg per deciliter, and LDL cholesterol ≤100 mg per deciliter if they could not receive statins without adverse effects; patients were randomly assigned 1:1 to pemafibrate 0.2-mg tablets twice daily or matching placebo, with median follow-up of 3.4 years.
- The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes; analysis used a likelihood-ratio test based on a proportional-hazards model stratified by sex, history of cardiovascular disease, and baseline statin use, with analysis of covariance for lipid changes.
Limitations
- The paper states that the data cannot rule out the possibility that observed increases in apolipoprotein B and LDL cholesterol levels in the pemafibrate group negated any benefit of reduction in triglyceride or remnant cholesterol levels.
- The trial was terminated early for futility after 75% of the target number of events had accrued, with median follow-up of 3.4 years; the text notes this termination but does not frame it as a limitation.
- Evident from the text: the trial population was 27.5% women and predominantly white (85.4% in the pemafibrate group and 86.4% in the placebo group), which may limit generalizability; the paper does not state this as a limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 6 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The data from the PROMINENT trial are consistent with increased efficiency in conversion of triglyceride-rich lipoprotein remnants to LDL rather than their removal by the liver. 21”
What the sources say
- Disputedcites [21] 21. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-806. sourceExperimental — accuracy not yet measured
The “Stimulating lipolysis” section says further insights were awaited from PROMINENT, rather than reporting data from it. The paper discusses conversion of remnants to LDL as a possible consequence of more efficient lipolysis, but does not attribute that finding to PROMINENT. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
What the sources say
- Partly supportedcites [2] 2. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020; 324: 2268-80. sourceExperimental — accuracy not yet measured
The Study Population section (p. 3) says participants in this trial were required to receive statins, supporting the claim for the STRENGTH trial. It does not establish that every other trial under discussion involved statin-treated patients or that FIELD was the sole exception. (LLM, conf=0.84)
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The AIM-HIGH paper reports statin use in its own trial: Table 1, reproduced in the Discussion passage, shows baseline use in 94.4% and 92.8% of the two groups. Our copy does not establish that all the other trials referred to by the citing sentence involved patients receiving statins, or that FIELD was the exception. (LLM, conf=0.83)
- Partly supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. sourceExperimental — accuracy not yet measured
The Methods (Study Design; page not available) say ACCORD Lipid assigned patients to simvastatin plus fenofibrate or placebo, supporting the claim for this trial. The Discussion (page not available) contrasts ACCORD with FIELD’s statin-therapy drop-in, but does not establish that all the other trials mentioned involved patients receiving statins. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
What the sources say
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The Discussion reports no significant reduction in cardiovascular events with extended-release niacin added to intensive statin therapy. However, the Lipid Levels section reports a 28.6% triglyceride decrease at two years in the niacin group, not 26%; Table 2 also gives no 26% decrease at years one or three. Our copy does not provide page numbers for these passages. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987; 83: 66-70. source
- Not checked — no full text of the sourcecites [18] 18. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-11. source
- Supportedcites [19] 19. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-35. source
The Discussion (page unavailable) says fibrates differ in their effects on VLDL secretion and clearance, while describing stimulation of lipoprotein lipase activity as a known fibrate effect. The Results likewise show that fenofibrate reduced VLDL-apoB secretion but did not change hepatic VLDL-TG secretion. Together, these passages support the cited comparison in consistency. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, our data further highlight the complexity of lipid mediators of residual risk among patients with insulin resistance who are receiving statin therapy. 6,23-25”
What the sources say
- Supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. source
The cited ACCORD Lipid paper provides background for the citing authors’ conclusion, rather than evidence about their own PROMINENT data. Its Results (Plasma Lipids and Clinical Outcomes; page unavailable) report lipid changes with fenofibrate added to simvastatin but no significant overall reduction in cardiovascular events; the Discussion describes a possible benefit in a dyslipidemic subgroup. These findings support the point that lipid-related residual risk in statin-treated patients with type 2 diabetes is complex. (LLM, conf=0.85)
- Supportedcites [23] 23. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370-80. source
The reference supports the cited background point, not the citing authors’ statement about their own PROMINENT data. The Introduction describes uncertain cardiovascular benefit from targeting triglycerides and HDL-C in statin-treated patients with type 2 diabetes; the Discussion describes mixed trial results, and the Results report a neutral overall fenofibrate effect but possible benefit in a dyslipidemic subgroup. (LLM, conf=0.88)
- Partly supportedcites [24] 24. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019; 21: 366-71. sourceExperimental — accuracy not yet measured
The Discussion reports that triglyceride levels were associated with residual cardiovascular events in statin-treated patients with diabetes despite controlled LDL cholesterol, supporting the background point about lipid-related residual risk. The study concerns patients with diabetes, not the broader population of patients with insulin resistance. The citing authors’ statement about what their own data highlight is not attributed to this source. (LLM, conf=0.82)
- Partly supportedcites [25] 25. Zhao Y, Xiang P, Coll B, López JAG, Wong ND. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications 2021; 35: 107767. Copyright © 2022 Massachusetts Medical Society. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report residual ASCVD risk in statin-treated patients with diabetes and identify lipoprotein(a) as a predictor of recurrent events. This supports a role for lipid-related risk, but the paper studies diabetes rather than insulin resistance broadly and does not establish lipid mediation of that residual risk. The citing sentence’s reference to “our data” is the citing authors’ own conclusion, not a claim about this source. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims
Create a free account to see all 81 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 22
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At a median follow-up of 3.4 years, pemafibrate lowered triglycerides by − 26%, VLDL by − 26%, remnant cholesterol by − 26% and ApoC-III by − 28% compared with placebo.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PROMINENT trial, in people with type 2 diabetes and elevated triglycerides (≥200 mg/dL and low HDL [≤40 mg/dL]), pemafibrate 0.2 mg twice daily reduced triglycerides by 26% but did not reduce the risk of the primary outcome of nonfatal MI, nonfatal stroke, hospitalization for unplanned coronary revascularization, or cardiovascular death (151).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, pemafibrate did not significantly reduce the risk of MACE (HR 1.03, 95% CI 0.91–1.15).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects on Lipid Levels and Other Key Biomarkers · p. 8
“Pemafibrate, as compared with placebo, also had similar effects on changes from baseline to 4 months and over time on levels of measured very-low-density lipoprotein (VLDL) cholesterol (-25.8%)”
§ Effects on Lipid Levels and Other Key Biomarkers · p. 7
“| VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ |”
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213
Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208
Self-citationFabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Self-citationIshibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184
Self-citationAraki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164
Self-citationFruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Self-citationNichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13537 · Cited by 125
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Self-citationA general inefficacy interim monitoring rule for randomized clinical trials
Freidlin, B., Korn, E. L., & Gray, R. (2010) · Clinical Trials · doi:10.1177/1740774510369019 · Cited by 64
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Self-citationChanges in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
Ginsberg, H. N. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90873-4 · Cited by 32
Self-citationKeech, A., & Field Study Investigators (2006) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(06)81349-8 · Cited by 28
Zhao, Y., Xiang, P., Coll, B., López, J. A. G., & Wong, N. D. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107767 · Cited by 19
Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14
Self-citationNichols, G. A., Philip, S., Granowitz, C. B., Reynolds, K., & Fazio, S. (2018) · Diabetes · doi:10.2337/db18-1485-p · Cited by 1
Ginsberg, H. N., Hounslow, N. J., Senko, Y., et al. (2022) · doi:10.2337/figshare.18028304
Self-citation
Cited by
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
“206 It has been speculated that this may be linked to greater reduction of apolipoprotein B concentrations with icosa-pent ethyl, 207 but more research on this topic is needed.”
BackgroundSelf-citationMartin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Self-citation
Metadata
- Authors
- Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., Brinton, E. A., Eckel, R. H., Elam, M. B., Felicio, J. S., Ginsberg, H. N., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., Koenig, W., Leiter, L. A., Lorenzatti, A. J., Mankovsky, B., Marx, N., Nordestgaard, B. G., Páll, D., Ray, K. K., Santos, R. D., Soran, H., Susekov, A., Tendera, M., Yokote, K., Paynter, N. P., Buring, J. E., Libby, P., & Ridker, P. M.
- Affiliations
- From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine (A.D.P., R.J.G., J.G.M., E.S.Z., B.M.E., N.P.P., J.E.B., P.M.R) and the Division of Cardiovascular Medicine (B.M.E.,P.L., P.M.R.), Brigham and Women’s Hospital, the Division of Cardiovascular Medicine, Veteran Affairs Boston Health Care System (A.D.P., J.J.), and Kowa Pharma Development (R.O.) — all in Boston; University of Lille, Lille (J.-C.F.) and the Department of Neurology and Stroke Center, Paris Cité University, Paris (P.A.) — both in France; Kowa Research Institute, Morrisville, NC (S.E.C.); the Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa (D.J.B.); Utah Lipid Center, Salt Lake City (E.A.B.); the University of Colorado School of Medicine, Aurora (R.H.E.); the University of Tennessee Health Science Center, Memphis (M.B.E.); the Division of Endocrinology, Universitário Hospital João de Barros Barreto, Belém (J.S.F.), and the Heart Institute (InCor), University of ...
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- ORCID
- Everett, Brendan M.
- Amarenco, Pierre
- Blom, Dirk J.
- Brinton, Eliot A.
- Eckel, Robert H.
- Elam, Marshall B.
- Ginsberg, Henry N.
- Goudev, Assen
- Ishibashi, Shun
- Joseph, Jacob
- Kodama, Tatsuhiko
- Leiter, Lawrence A.
- Lorenzatti, Alberto J.
- Mankovsky, Boris
- Marx, Nikolaus
- Nordestgaard, Børge G.
- Páll, Dénes
- Ray, Kausik K.
- Santos, Raul D.
- Soran, Handrean
- Susekov, Andrey
- Yokote, Koutaro
- Paynter, Nina P.
- Buring, Julie E.
- Libby, Peter
- Ridker, Paul M
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-11-24
- Volume
- 387
- Issue
- 21
- Pages
- 1923-1934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4308367139
- Semantic Scholar
- 2a5f509a3e50569b803a22d0dee824c145e73e75
- Cited by
- 749
- References
- 25
- Citations by year
- 2026: 153 · 2025: 185 · 2024: 191 · 2023: 208 · 2022: 10
- FWCI
- 142.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Kowa Research Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- pemafibrate, hypertriglyceridemia, type 2 diabetes, PPARα agonist, triglyceride lowering, cardiovascular risk reduction, cardiovascular events, HDL cholesterol, remnant cholesterol, apolipoprotein C-III, apolipoprotein B, VLDL cholesterol, renal adverse effects, venous thromboembolism, lipid-lowering therapy, statin intolerance
- MeSH terms
- Heart Disease Risk Factors, Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.